摘要
近年来有研究证实新型降糖药钠-葡萄糖协同转运蛋白(SGLT)-2抑制剂和胰高糖素样肽(GLP)-1受体激动剂具有心血管安全性方面的优势,因此推荐2型糖尿病(T2DM)合并心血管疾病或具有极高心血管风险的患者应用SGLT-2抑制剂或GLP-1受体激动剂以减少心血管事件。本文就新型降糖药心血管安全性研究的进展作一综述。
In recent years,studies have confirmed that novel hypoglycemic agents:sodium-glucose cotransporter(SGLT)-2 inhibitors and glucagon-like peptide(GLP)-1 receptor agonists possess advantages in cardiovascular safety,so it is recommended that patients with type 2 diabetes mellitus complicated cardiovascular disease(CVD)or those with extremely high cardiovascular risk should use SGLT-2 inhibitors or GLP-1 receptor agonists to reduce cardiovascular events.The present article makes a review for research progress of novel hypoglycemic agents on cardiovascular safety.
作者
张馨蕾
张瑶
ZHANG Xin-lei;ZHANG Yao(Department of Cardiology,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)
出处
《心血管康复医学杂志》
CAS
2021年第5期613-616,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心血管疾病
糖尿病
2型
降血糖药
Cardiovascular Diseases
Diabetes Mellitus,Type 2
Hypoglycemic Agents
